Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Shimada T, Tsuya A, Fukuoka M, Minami H. Uryu K, et al. Among authors: shimoyama r. Cancer Chemother Pharmacol. 2024 Aug;94(2):197-208. doi: 10.1007/s00280-024-04666-4. Epub 2024 Apr 8. Cancer Chemother Pharmacol. 2024. PMID: 38584202
Risk Factors for Adhesive Small Bowel Obstruction After Liver Cancer Surgery.
Yukawa N, Yamada T, Ichikawa D, Aoyama T, Kataoka K, Shioya T, Tamura T, Shimoyama R, Fukazawa A, Kumamoto K, Yamashita N, Hasegawa S, Saito S, Takemasa I, Fujita F, Taniai N, Kaibori M, Yoshida H. Yukawa N, et al. Among authors: shimoyama r. Cancer Diagn Progn. 2024 Nov 3;4(6):689-695. doi: 10.21873/cdp.10383. eCollection 2024 Nov-Dec. Cancer Diagn Progn. 2024. PMID: 39502609 Free PMC article.
Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: The Biobank Japan Project.
Okada E, Ukawa S, Nakamura K, Hirata M, Nagai A, Matsuda K, Ninomiya T, Kiyohara Y, Muto K, Kamatani Y, Yamagata Z, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group; Tamakoshi A. Okada E, et al. J Epidemiol. 2017 Mar;27(3S):S29-S35. doi: 10.1016/j.je.2016.12.002. Epub 2017 Feb 9. J Epidemiol. 2017. PMID: 28190659 Free PMC article.
Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Tsuya A, Okabe T, Fukuoka M, Minami H. Uryu K, et al. Among authors: shimoyama r. Jpn J Clin Oncol. 2024 Dec 1:hyae167. doi: 10.1093/jjco/hyae167. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39673402
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
Hibino M, Imamura Y, Shimoyama R, Fukui T, Fukai R, Iwase A, Tamura Y, Chihara Y, Okabe T, Uryu K, Okuda T, Taguri M, Minami H. Hibino M, et al. Among authors: shimoyama r. Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20. Target Oncol. 2024. PMID: 39302602 Free PMC article.
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H. Uryu K, et al. Among authors: shimoyama r. Jpn J Clin Oncol. 2024 Mar 9;54(3):319-328. doi: 10.1093/jjco/hyad162. Jpn J Clin Oncol. 2024. PMID: 37997468
104 results